

Case	Age (years)	Duration of epilepsy (years)	Epileptogenic focus	Etiology	Previous surgical procedure	Previous ASM	Concomitant ASM (mg/day)	Mean of seizures/month before CNB	Mean of seizures/month on last follow-up	Follow-up (days)	Dose of CNB at last follow-up (mg/day)	Dose of CLB in last follow-up (mg/day)	Median of Seizure frequency reduction %
1	35	17	Right Frontal lobe	FCD Type I	No	7	ZNS (400 mg) LCS (400 mg) PRP (6 mg) CLB (15 mg)	4	4	333	250	15	No change
2	43	31	Right Frontal lobe	FCD Type I	No	10	CBZ (800 mg) BRV (200 mg) CLB (30 mg)	16	2	136	150	10	87%
3	17	9	Frontal bilateral	Generic-based epileptic encephalopathy	No	5	LCS (200 mg) CLB (15 mg)	600	400	160	150	15	33%
4	60	57	Right Temporal lobe	Right Medial Temporal Sclerosis	No	6	LCS (400 mg) VPA (1000 mg) CLB (15 mg)	4	3	83	100	15	25%
5	38	13	Left Temporal lobe	Non-lesional focal epilepsy	No	8	BRV (200 mg) ESL (800 mg) CLB (10 mg)	8	8	217	150	10	No change
6	58	42	Temporal bilateral	Subependimary heterotopia	No	7	LCS (300 mg) LEV (2000 mg) ESL (1200 mg) CLB (40 mg)	30	1	325	150	30	96%
7	34	16	Temporal bilateral	Non-lesional focal epilepsy	No	7	LCS (300 mg) BRV (200 mg)	4	4	158	150	15	No change
8	17	17	Temporal bilateral	Type II FCD	Yes	7	ESL (1200 mg) LCS (400 mg)	12	6	113	200	15	50%

							CLB (30 mg)						
9	42	28	Right Temporal lobe	Focal non-lesional epilepsy	No	11	LCS (400 mg) PRP (6 mg) CLB (20 mg)	30	6	258	150	20	80%
10	32	26	Multifocal	Focal non-lesional epilepsy	No	10	BRV (100 mg) ESL (1200 mg) LMT (200 mg) CLB (5 mg)	6	2	96	250	5	33%
11	57	40	Temporal bilateral	Focal non-lesional epilepsy	No	7	CBZ (600 mg) BRV (200 mg) PRP (6 mg) CLB (20 mg)	4	0	332	200	20	Free
12	39	14	Temporal	Focal non-lesional epilepsy	No	8	LMG (450 mg) ESL (1200 mg) PRP (4 mg) CLB (10 mg)	7	0	111	300	5	Free
13	41	11	Temporal bilateral	Focal non-lesional epilepsy	No	7	LCS (300 mg) CLB (10 mg)	2	0	96	250	5	Free
14	34	25	Temporal bilateral	Disembrioblastic Neuroepithelial Tumour	No	8	CBZ (800 mg) BRV (200 mg) CLB (20 mg)	50	30	143	150	20	40%
15	36	21	Left Temporal lobe	Schizencephaly	No	4	BRV (200 mg) PRP (8 mg) CLB (20 mg)	30	20	84	100	10	33%
16	17	17	Left Temporal lobe	Epileptic encephalopathy	No	9	PRP (4 mg) VPA (1500 mg) LCS (300 mg) CLB (20 mg)	30	10	84	150	10	66%

17	23	5	Left Temporal lobe	Focal non-lesional epilepsy	No	8	ESL (1200 mg) PRP (6 mg) CLB (20 mg)	30	25	115	50	25	16%
18	36	21	Left Temporal lobe	Type I FCD	No	11	LCS (400 mg) BRV (200 mg) CLB (20 mg)	8	1	83	200	20	87%
19	52	6	Left Temporal lobe	Mesial Temporal Sclerosis	No	3	LCS (300) BRV (150 mg) CLB (5 mg)	8	6	117	150	10	25%
20	41	24	Left Temporal lobe	Focal non-lesional epilepsy	No	6	ESL (1200 mg) BRV (200 mg) CLB (30 mg)	2	1	333	150	5	50%

eTable 1. Clinical and demographic data of control group. BRV: Brivaracetam. CBZ: Carbamazepine. CLB: Clobazam. CZN: Clonazepam. ESL: Eslicarbazepine acetate. LCS: Lacosamide. LEV: Levetiracetam. LTG: Lamotrigine. OXC: Oxcarbazepine. PER: Perampanel. TPM: Topiramate. VPA: Valproic Acid.